WUHAN HZYMES BIOTECHNOLOGY CO LTD

Overview

WUHAN HZYMES BIOTECHNOLOGY CO LTD is an active pharmaceutical ingredient (API) supplier with 17 active FDA Type II Drug Master Files, covering BSA I RESTRICTION ENDONUCLEASE; BSPQI; DNASE I,RNASE-FREE; GLP-1(9-37) (LYOPHILIZED POWDER); mRNA Cap 2 -OMETHYLTRANSFERASE; PYROPHOSPHATASE INORGANIC (YEAST).

API / Drug Master Files

WUHAN HZYMES BIOTECHNOLOGY CO LTD holds 17 active (17 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• T7 RNA POLYMERASEActive2026-03-22
• T7 RNA POLYMERASE (LOW DSRNA)Active2026-03-22
• BSPQIActive2026-03-22
• T7 RNA POLYMERASE (THERMOSTABLE)Active2026-03-22
• DNASE I,RNASE-FREEActive2026-03-22
• GLP-1(9-37) (LYOPHILIZED POWDER)Active2025-10-22
• SEMAGLUTIDE MAIN CHAINActive2024-02-06
• RECOMBINANT TRYPSIN DIGESTION SOLUTIONActive2024-01-22
• BSA I RESTRICTION ENDONUCLEASEActive2024-01-22
• SEMAGLUTIDEActive2023-11-10
• RECOMBINANT TRYPSIN/RECOMBINANT TRYPSIN SOLUTIONActive2023-06-16
• VACCINIA CAPPING ENZYMEActive2022-04-07
• mRNA Cap 2 -OMETHYLTRANSFERASEActive2022-04-07
• PYROPHOSPHATASE INORGANIC (YEAST)Active2022-04-04
• T7 RNA POLYMERASEActive2022-04-04

Showing 15 of 17 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to WUHAN HZYMES BIOTECHNOLOGY CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.